Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial

Peer Review reports

Original Submission
25 Sep 2021	Submitted	Original manuscript
10 Feb 2022	Reviewed	Reviewer Report - Alexander Gough
20 Mar 2022	Reviewed	Reviewer Report - SHIVALINGAPPA JAMBOTI
23 Mar 2022	Author responded	Author comments - Katharina A Mayer
Resubmission - Version 2
23 Mar 2022	Submitted	Manuscript version 2
Publishing
25 Mar 2022	Editorially accepted
8 Apr 2022	Article published	10.1186/s13063-022-06198-9

Back to article page